Dr. David M. Barrett Joins ProUroCare Board of Directors

  Dr. David M. Barrett Joins ProUroCare Board of Directors

Business Wire

MINNEAPOLIS -- November 05, 2012

ProUroCare Medical Inc. (OCTQB: PUMD), a provider of proprietary medical
imaging products, today announced that Dr. David M. Barrett, MD, was elected
to ProUroCare’s Board of Directors at their quarterly board meeting. He is the
former President and CEO of the Lahey Clinic in Burlington, Massachusetts,
which is one of the largest medical centers in New England. In addition to his
urology practice, Dr. Barrett currently sits on the Board of Directors of
Advantedge Healthcare Solutions, Inc., CR Bard Inc., Commonfund, Inc.,
Sapphire Systems, Inc. and Juliet Marine, Inc. He is a Member of the Life
Sciences Advisory Board of Safeguard Scientifics, Inc. and is the former
Chairman of the Massachusetts Hospital Association.

“Dr. Barrett’s years of experience in leadership roles at the nation’s top
medical centers, his insights as a practicing urologist and his extensive
business and medical experience make him an ideal candidate to help ProUroCare
as we seek to commercialize our mechanical imaging technology,” said Rick
Carlson, ProUroCare’s CEO. “Dr. Barrett is also uniquely qualified to work
with a developing medical products company that has a broad technology
platform from which numerous medical products can be developed, helping us
achieve our goal of transforming the diagnosis, monitoring and management of
prostate disease.”

“ProUroCare is an exciting early stage technology company,” said Dr. Barrett.
“I’m looking forward to working with Rick, ProUroCare’s board and its numerous
medical technology advisors and key opinion leaders in urology to help build a
truly great company in the years ahead.”

Dr. Barrett is a Clinical Professor of surgery at the Dartmouth Medical School
and a staff urologist at the Dartmouth Hitchcock Medical Center. Dr. Barrett
began working at Mayo Clinic (Rochester, Minnesota) as a staff physician in
1975. He was Chair of the Department of Urology of Mayo Clinic, where he
served on the Board of Trustees and as Vice Chair of the Board of Governors.
From 1970 to 1972, Dr. Barrett served as a flight surgeon during the Vietnam
War, and became Chief of the Aeromedical Service at Cam Rahn Bay Air Base. He
is a former Trustee at Albion College.

Dr. Barrett is an authority on urologic oncology, urinary incontinence,
bladder reconstruction, and genitourinary prostheses. During the course of his
career, he has been widely published in academic journals and has received
numerous research grants and contracts. Among his many professional
affiliations are memberships in the American College of Surgeons, the American
Urologic Association, and the American College of Healthcare Executives. He is
a past president of the American Board of Urology. Dr. Barrett received his
B.A. from Albion College and his M.D. from Wayne State University School of
Medicine.

Dr. Barrett replaces retiring director David Koenig, who will continue to act
as ProUroCare’s Corporate Secretary. Dr. Barrett will serve on ProUroCare’s
Governance and Nominating Committee.

About ProUroCare Medical Inc.

ProUroCare Medical Inc. is a publicly traded company engaged in the business
of creating innovative medical imaging products. The company’s ProUroScan
system, an elasticity imaging technology used to document abnormalities of the
prostate previously detected by a digital rectal examination, received
commercial clearance from the FDA on April 27, 2012. Based in Minneapolis, the
company’s stock trades on the OTCQB market (www.otcmarkets.com).

This news release contains certain "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements are typically preceded by words such as "believes," "expects,"
"anticipates," "intends," "will," "may," "should," or similar expressions.
These forward-looking statements are not guarantees of ProUroCare's future
performance and involve a number of risks and uncertainties that may cause
actual results to differ materially from the results discussed in these
statements. Factors that might cause ProUroCare's results to differ materially
from those expressed or implied by such forward looking statements include,
but are not limited to, the ability of ProUroCare to find adequate financing
to complete the development of its products; the high level of secured and
unsecured debt incurred by ProUroCare; the impact and timing of actions taken
by the FDA and other regulatory agencies with respect to ProUroCare’s products
and business; the dependence by ProUroCare on third parties for the
development and manufacture of its products; and other risks and uncertainties
detailed from time to time in ProUroCare's filings with the Securities and
Exchange Commission including its most recently filed Form 10-K and Form 10-Q.
ProUroCare undertakes no duty to update any of these forward-looking
statements.

Contact:

ProUroCare Medical Inc.
Rick Carlson, 952-476-9093
Chief Executive Officer
rcarlson@prourocare.com
 
Press spacebar to pause and continue. Press esc to stop.